Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOCATION: Local delivery of CER-001 in advanced atherosclerotic plaques
NL-OMON22856Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CER-001 in atherosclerosis and Vasculopathy, sponsored by Amsterdam University Medical Center. Primary endpoint: Plaque uptake of 89Zr-CER-001 over time. Started Jul 2014; status: active, not recruiting.
02
Drugs
CER-001
03
Conditions
atherosclerosisVasculopathy
Beyond the preview
Go deeper on NL-OMON22856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22856.